Cargando…
Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland
Tricuspid regurgitation (TR) usually develops secondarily to left-sided heart diseases, whereas primary lesions to the valve apparatus is less common. Untreated severe TR has a poor prognosis and surgical treatment, i.e., valve repair or replacement, is the only treatment option with class I recomme...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Via Medica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170310/ https://www.ncbi.nlm.nih.gov/pubmed/34671966 http://dx.doi.org/10.5603/CJ.a2021.0130 |
_version_ | 1784721393923915776 |
---|---|
author | Witkowski, Adam Dudek, Dariusz Bartuś, Stanisław Wojakowski, Wojciech Gackowski, Andrzej Grygier, Marek Kuśmierczyk, Mariusz Jaguszewski, Miłosz J. Kowalik, Ewa Bondaryk, Katarzyna Niewada, Maciej Przygodzki, Piotr Jakubczyk, Michał |
author_facet | Witkowski, Adam Dudek, Dariusz Bartuś, Stanisław Wojakowski, Wojciech Gackowski, Andrzej Grygier, Marek Kuśmierczyk, Mariusz Jaguszewski, Miłosz J. Kowalik, Ewa Bondaryk, Katarzyna Niewada, Maciej Przygodzki, Piotr Jakubczyk, Michał |
author_sort | Witkowski, Adam |
collection | PubMed |
description | Tricuspid regurgitation (TR) usually develops secondarily to left-sided heart diseases, whereas primary lesions to the valve apparatus is less common. Untreated severe TR has a poor prognosis and surgical treatment, i.e., valve repair or replacement, is the only treatment option with class I recommendation. However, cardiac surgical procedures may be associated with a high risk of complications. Recent advances in percutaneous approaches to managing structural heart diseases, especially mitral valve diseases, have enabled the implementation of this therapeutic strategy in the population of patients with TR. This paper presents data on the clinical efficacy, cost-effectiveness and expected population size for one of these procedures, namely the TriClip TTVr System procedure. Its efficacy was assessed in the TRILUMINATE study involving 85 patients with co-morbidities and at high surgical risk. After 1 year of follow-up, the reduction in the TR grade was reported in 71% of patients. Clinical improvement in New York Heart Association functional class, a 6-minute walk test, and the quality of life were also observed. A published analysis comparing percutaneous treatment modalities with a drug therapy based on data from medical registers was utilized, and propensity score matching was also employed. Percutaneous treatment reduced 1-year mortality and rehospitalization risk. The economic analysis showed the use of TriClip TTVr System is cost-effective: the cost of an additional quality-adjusted life year ranged from approximately PLN 85,000 to PLN 100,000, which is below the official threshold in Poland. The potential annual number of candidates for this treatment modality in Poland is estimated at 265. |
format | Online Article Text |
id | pubmed-9170310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Via Medica |
record_format | MEDLINE/PubMed |
spelling | pubmed-91703102022-06-07 Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland Witkowski, Adam Dudek, Dariusz Bartuś, Stanisław Wojakowski, Wojciech Gackowski, Andrzej Grygier, Marek Kuśmierczyk, Mariusz Jaguszewski, Miłosz J. Kowalik, Ewa Bondaryk, Katarzyna Niewada, Maciej Przygodzki, Piotr Jakubczyk, Michał Cardiol J Review Article Tricuspid regurgitation (TR) usually develops secondarily to left-sided heart diseases, whereas primary lesions to the valve apparatus is less common. Untreated severe TR has a poor prognosis and surgical treatment, i.e., valve repair or replacement, is the only treatment option with class I recommendation. However, cardiac surgical procedures may be associated with a high risk of complications. Recent advances in percutaneous approaches to managing structural heart diseases, especially mitral valve diseases, have enabled the implementation of this therapeutic strategy in the population of patients with TR. This paper presents data on the clinical efficacy, cost-effectiveness and expected population size for one of these procedures, namely the TriClip TTVr System procedure. Its efficacy was assessed in the TRILUMINATE study involving 85 patients with co-morbidities and at high surgical risk. After 1 year of follow-up, the reduction in the TR grade was reported in 71% of patients. Clinical improvement in New York Heart Association functional class, a 6-minute walk test, and the quality of life were also observed. A published analysis comparing percutaneous treatment modalities with a drug therapy based on data from medical registers was utilized, and propensity score matching was also employed. Percutaneous treatment reduced 1-year mortality and rehospitalization risk. The economic analysis showed the use of TriClip TTVr System is cost-effective: the cost of an additional quality-adjusted life year ranged from approximately PLN 85,000 to PLN 100,000, which is below the official threshold in Poland. The potential annual number of candidates for this treatment modality in Poland is estimated at 265. Via Medica 2022-05-31 /pmc/articles/PMC9170310/ /pubmed/34671966 http://dx.doi.org/10.5603/CJ.a2021.0130 Text en Copyright © 2022 Via Medica https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially |
spellingShingle | Review Article Witkowski, Adam Dudek, Dariusz Bartuś, Stanisław Wojakowski, Wojciech Gackowski, Andrzej Grygier, Marek Kuśmierczyk, Mariusz Jaguszewski, Miłosz J. Kowalik, Ewa Bondaryk, Katarzyna Niewada, Maciej Przygodzki, Piotr Jakubczyk, Michał Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland |
title | Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland |
title_full | Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland |
title_fullStr | Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland |
title_full_unstemmed | Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland |
title_short | Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland |
title_sort | innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in poland |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170310/ https://www.ncbi.nlm.nih.gov/pubmed/34671966 http://dx.doi.org/10.5603/CJ.a2021.0130 |
work_keys_str_mv | AT witkowskiadam innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT dudekdariusz innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT bartusstanisław innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT wojakowskiwojciech innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT gackowskiandrzej innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT grygiermarek innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT kusmierczykmariusz innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT jaguszewskimiłoszj innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT kowalikewa innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT bondarykkatarzyna innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT niewadamaciej innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT przygodzkipiotr innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland AT jakubczykmichał innovativemedicaltechnologiesinthepercutaneoustreatmentoftricuspidregurgitationinpoland |